AbbVie

ThirtyFiveBio is a biotechnology company focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, an area marked by significant unmet clinical needs. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify contemporary small-molecule modulators of specific proteins, particularly targeting GPR35 signaling pathways. By addressing the challenges associated with digestive system malignancies, ThirtyFiveBio aims to offer therapeutic solutions that could help prevent tumor growth and improve patient outcomes.

Cephagenix is a biopharmaceutical company dedicated to discovering and developing innovative therapies for migraine. It specializes in identifying and advancing selective inhibitors of the adenosine triphosphate-sensitive potassium channel subtype expressed in intracranial arteries, which have shown promise in preclinical migraine models. The company's mission is to address the underlying mechanisms of migraine, aiming to provide effective treatments for individuals suffering from this debilitating condition.

Light Horse Therapeutics is a biotechnology company specializing in the application of gene editing to small-molecule drug discovery. It develops innovative methods to target the root causes of severe and life-threatening diseases, with an initial focus on challenging oncology targets. The company's advanced platform identifies critical functional domains within disease-related proteins, enabling the development of more effective therapies.

Nimble Therapeutics is a biotechnology company focused on advancing drug discovery through its innovative maskless chemical synthesis platform. This technology enables the systematic synthesis and discovery of novel medicines across various therapeutic areas. By leveraging massively parallel chemical synthesis, Nimble Therapeutics aids in the empirical optimization of molecules, enhancing their drug-like properties. The company's approach is designed to transform the way peptide therapeutics are developed, providing medical professionals with the tools necessary for intelligent discovery and development of next-generation therapies.

Aliada Therapeutics is a biotechnology company focused on developing innovative therapies for central nervous system (CNS) diseases. Established in 2021 and headquartered in Boston, Massachusetts, the company leverages its proprietary technology to create specific antibody binders targeting CNS conditions. By advancing its programs through preclinical evaluation, Aliada Therapeutics aims to provide effective treatment options for medical professionals addressing CNS-related disorders.

Oisin Biotechnologies, Inc. is a biotechnology company based in Seattle, Washington, established in 2014, that specializes in developing therapies aimed at addressing age-related diseases through the elimination of senescent cells. The company utilizes a proprietary technology platform known as SENSOlytics, which enables the precise targeting of senescent cells based on their DNA expression, distinguishing them from healthy cells. Oisin Biotechnologies is advancing a range of interventions, including a lead program that targets frailty by promoting muscle growth independent of exercise and another that selectively eliminates fat cells. The company's innovative approach employs a non-viral delivery system, facilitating the effective distribution of DNA and RNA-based therapies to combat various age-related conditions. Research indicates that the clearance of senescent cells not only mitigates the adverse effects of aging but may also extend lifespan and enhance overall health.

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Blacksburg, Virginia, focused on developing innovative oral therapeutics for autoimmune diseases, particularly inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. Founded in 2017, the company aims to address unmet medical needs through its unique approach to treatment, leveraging novel mechanisms of action. Its lead product candidate, NX-13, is a gut-selective NLRX1 agonist designed to modulate immune responses, and it is part of a broader pipeline that includes other internally discovered compounds targeting various pathways at the intersection of immunity and metabolism. Landos Biopharma's commitment to developing first-in-class therapeutics underscores its dedication to improving patient outcomes in the field of autoimmune disorders.

BaseLaunch is a venture builder firm located in Basel, Switzerland, focused on launching and developing startups across various therapeutic sectors, including oncology, immunology, and cardiovascular health. The program spans 15 months and is divided into two phases, providing non-dilutive funding and access to a network of leading healthcare partners. Participants benefit from the expertise of seasoned advisors and state-of-the-art infrastructure, while being integrated into Basel's vibrant biotech ecosystem. BaseLaunch is supported by prominent industry leaders such as Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer, Roche, and Roivant Sciences, along with various public and private collaborators.

DISCO Pharmaceuticals is a biotechnology company focused on advancing cancer treatment through its innovative surfaceome mapping platform. The firm specializes in large-scale surfaceome unlocking of cancer cells, utilizing transformative cell discovery technology to identify proteins and protein communities present on the surface of cancer cells. This scalable approach allows for the extraction of comprehensive target information that traditional proteomics, genome, or transcriptome sequencing methods cannot provide. By leveraging this technology, DISCO Pharmaceuticals aims to enable the development of cancer-selective therapies, potentially enhancing treatment efficacy while minimizing side effects for patients.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

ImmunoGen, Inc. is a clinical-stage biotechnology company based in Waltham, Massachusetts, specializing in the development of antibody-drug conjugate (ADC) therapies for cancer treatment. The company utilizes its proprietary Targeted Antibody Payload (TAP) technology to create therapeutics that deliver potent cytotoxic agents directly to tumor cells. Key product candidates include mirvetuximab soravtansine, currently undergoing Phase III trials for platinum-resistant ovarian cancer, and IMGN632, a CD123-targeting ADC in Phase I trials for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen is also advancing several preclinical programs, such as IMGC936 in collaboration with MacroGenics. The company has established numerous collaborations with major pharmaceutical firms, enhancing its research and development capabilities. Founded in 1980, ImmunoGen is dedicated to innovating cancer therapies that improve patient outcomes.

Mozart Therapeutics is a biotechnology startup dedicated to developing innovative therapies for autoimmune and inflammatory diseases. The company specializes in creating disease-modifying CD8 T cell modulators, leveraging a unique regulatory CD8 T cell network to target a specific subset of T lymphocytes. These modulators aim to restore immune balance and mitigate the damage caused by autoreactive and pathogenic immune responses. By focusing on first-in-class CD8 Treg modulators, Mozart Therapeutics seeks to delay the onset and improve the management of various autoimmune disorders, thereby providing healthcare professionals with advanced treatment options for their patients.

Quanta Therapeutics is a biotechnology company focused on developing innovative cancer therapies targeting driver oncogenes, specifically those associated with RAS-driven cancers. The company employs an advanced platform that utilizes optical technology to identify small molecules capable of modulating the conformation of RAS proteins. This approach allows for the restoration of conformational control of active RAS signaling at the cell membrane, which is crucial in inhibiting the progression of various RAS-driven cancer types. Through its novel therapeutic candidates, Quanta aims to provide effective treatment options for cancers that have previously been deemed untreatable.

Capsida is a biotechnology company focused on developing targeted gene therapies for monogenic and sporadic disorders affecting both the central nervous system and other areas of the body. The company utilizes a proprietary adeno-associated virus (AAV) engineering platform, which creates capsids specifically designed to target particular tissues and cells within affected organs. This advanced approach not only aims to enhance the efficacy of the therapies by ensuring they reach the intended sites of action, but also minimizes the impact on non-target tissues, thereby improving patient health outcomes in the treatment of life-threatening genetic disorders.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

DJS Antibodies Ltd is a biotechnology company based in Bicester, United Kingdom, established in 2014. The company focuses on the design and discovery of novel therapeutic monoclonal antibodies specifically targeting G-protein-coupled receptors (GPCRs). DJS Antibodies aims to develop innovative therapeutics for chronic inflammatory diseases by utilizing its advanced technology to create first-in-class antibody therapeutics for previously challenging disease targets. By specializing in the research and discovery of functional antibodies against complex protein targets that have eluded traditional drug discovery efforts, DJS Antibodies endeavors to provide effective treatments for diseases that are currently considered undruggable and untreatable.

Syndesi Therapeutics SA is a biotechnology company based in Louvain-la-Neuve, Belgium, founded in 2018. The company specializes in developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that enables communication between neurons in the brain. This innovative approach aims to address cognitive impairments associated with conditions such as Alzheimer’s Disease. Syndesi Therapeutics holds an exclusive license for its platform technology from UCB, a leader in SV2A research, positioning the company to advance therapeutic options for patients suffering from cognitive disorders.

Ambagon Therapeutics is a biotechnology company focused on developing small-molecule therapeutics for cancer treatment. The company specializes in research aimed at stabilizing the interactions of oncogenic proteins, which are often difficult to modulate with traditional methods. By selectively enhancing the activity of tumor-suppressing proteins associated with transcription factors and oncoproteins, Ambagon aims to provide new therapeutic options for addressing significant unmet clinical needs in oncology. Founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin, the company is dedicated to advancing innovative solutions in cancer care.

Nitrase Therapeutics is a biopharmaceutical company focused on developing innovative therapies targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create treatments that may slow or halt the progression of this condition. The company leverages its proprietary platform, which is based on the biochemical modification of proteins through nitration, to identify nitro-substrates and their relevance in various diseases. This approach not only addresses Parkinson's but also positions Nitrase to expand its research into other therapeutic indications, with the goal of offering novel medicines that target this specific enzyme pathway.

Quanta Therapeutics is a biotechnology company focused on developing innovative cancer therapies targeting driver oncogenes, specifically those associated with RAS-driven cancers. The company employs an advanced platform that utilizes optical technology to identify small molecules capable of modulating the conformation of RAS proteins. This approach allows for the restoration of conformational control of active RAS signaling at the cell membrane, which is crucial in inhibiting the progression of various RAS-driven cancer types. Through its novel therapeutic candidates, Quanta aims to provide effective treatment options for cancers that have previously been deemed untreatable.

The Institute for Family Health is offering mental health, dental care, and social services.

For more than 157 years, Eskenazi Health has offered high-quality, cost-effective and patient-focused health care to the residents of Marion County and Central Indiana. As one of America’s largest essential health-care systems, Eskenazi Health provides treatment and services to nearly 1 million outpatient visitors each year.

Community Hope is helping individuals, including veterans, and their families, overcome mental illness, addiction, homelessness, and poverty by providing housing and support services. Homeless veterans suffering from mental health issues and combat-induced trauma have been able to access their residential programs and support services.

The Night Ministry is a nonprofit organization that provides housing, health care, and social services.

Delaware Valley Community Health operates as a non-profit firm, the firm offers adult & family medicine, pediatrics, dental, etc. services.

Aaron E. Henry Community Health Services Center offers primary and preventive health care services.

MLK Health Center provides general health care services. They offer services in routine physical exams, prescribing necessary medications, treatment of minor illnesses and injuries, managing chronic conditions, screening for common health issues, and management of acute health conditions. They also offer a thorough assessment of patient data, disease data, and medicine-related data where patient-specific medicine-related problems are identified, including ineffective dosages, non-adherence, and adverse drug reactions.

Roanoke Chowan Community Health Center is a private healthcare provider located in Ahoskie, North Carolina. The center offers a range of services designed to improve community health, including behavioral health, pharmacy, telehealth, and clinical and pediatric care. By focusing on comprehensive health services, Roanoke Chowan Community Health Center aims to meet the diverse needs of its patients and enhance overall wellness in the region.

Health Brigade is a non-profit organization that provides health services. Their services include wellness, health outreach, advocacy, needle exchange, and eligibility for services. They provide adult general medicine, including medical services for diabetes, high blood pressure, asthma, men’s health, psychiatric evaluation and medication, routine cancer screening, and chronic heart disease.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Starday Foods is a company focused on producing healthy and sustainable food products. It emphasizes sustainable practices in its operations, which enhances the speed and efficiency of food and beverage product development. The company is committed to creating food items that are low in sugar and free from palm oil and dairy, thereby catering to consumers seeking quality ingredients. Starday Foods aims to minimize its environmental impact while providing nutritious options for health-conscious individuals.

Stemson Therapeutics, LLC is a cell therapy company focused on restoring natural hair through innovative techniques. Established in 2018 and based in La Jolla, California, the company specializes in generating new hair follicles using a proprietary method that involves induced pluripotent stem cells (iPSC) to create dermal papilla cells. These engineered cells, combined with a unique tissue engineering solution, allow for the generation of new hair follicles, providing a potential cure for individuals experiencing hair loss and its associated emotional and social challenges. Stemson Therapeutics aims to offer patients a safe and effective means to combat hair loss by delivering a new supply of hair follicles.

Kojin Therapeutics, founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, focuses on advancing a drug discovery platform that links complex cell states to established biochemical processes, specifically ferroptosis, which involves iron-dependent cell death. This innovative approach enables the development of targeted therapies for a wide range of challenging diseases that are often difficult to treat. The company's biology platform aims to identify disease-specific targets, ensuring that patients receive effective treatments tailored to their specific conditions. Kojin Therapeutics is supported by a diverse group of investors, including Polaris Partners, Newpath Partners, and AbbVie, among others.

Capsida is a biotechnology company focused on developing targeted gene therapies for monogenic and sporadic disorders affecting both the central nervous system and other areas of the body. The company utilizes a proprietary adeno-associated virus (AAV) engineering platform, which creates capsids specifically designed to target particular tissues and cells within affected organs. This advanced approach not only aims to enhance the efficacy of the therapies by ensuring they reach the intended sites of action, but also minimizes the impact on non-target tissues, thereby improving patient health outcomes in the treatment of life-threatening genetic disorders.

Mitokinin, Inc. is a biotechnology company based in New York, focused on developing small molecule therapeutics aimed at treating neurodegenerative diseases, particularly Parkinson's disease. The company specializes in medicinal chemistry to create kinetin analogs that optimize the activation of PINK1, a protein involved in cellular health. Mitokinin's compounds are designed to enhance the activity of active-form PINK1 without interfering with its natural regulation. Founded in 2017, the company comprises a team of neuroscientists, chemists, and pharmacologists dedicated to advancing disease-modifying therapies in the healthcare sector.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Faze Medicines is a biotechnology company based in Cambridge, Massachusetts, founded in 2020. It focuses on developing small molecule drugs targeting key drivers of disease pathology, with initial therapeutic areas including amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). The company employs advanced screening and proteomics techniques to define condensate interaction networks, aiming to pioneer innovative therapeutics based on biomolecular condensates. Through its research, Faze Medicines seeks to provide effective treatments for complex diseases such as ALS and frontotemporal dementia (FTD).

Year Up is a nonprofit organization focused on closing the Opportunity Divide by equipping urban young adults with essential skills and professional experience. It offers tuition-free, skills-based training programs that include internships with partner companies and comprehensive job search support. By empowering participants to develop their capabilities, Year Up aims to facilitate their entry into meaningful careers or higher education, ultimately helping them to realize their full potential.

Palleon Pharmaceuticals Inc. is a biotechnology company dedicated to developing innovative therapeutics that target glycan-mediated immune regulation for the treatment of cancer and inflammatory diseases. Founded in 2015 and based in Waltham, Massachusetts, the company specializes in glycoimmune checkpoint inhibitors, leveraging advanced insights from glycoscience and human immunology. Palleon's biotechnology platform aims to provide a novel approach to cancer treatment by targeting various immune cell types, thus offering physicians an expanded array of combination therapies to enhance treatment efficacy and address resistance to existing immuno-oncology agents. In addition to cancer, the company also focuses on therapeutics for inflammatory diseases, including autoimmunity and fibrosis.

Enthera is an Italian biotechnology startup established in October 2016 by BiovelocITA, Professor Paolo Fiorina, and Dr. Francesca D'Addio. The company specializes in developing biotherapeutics aimed at treating autoimmune disorders, with a focus on type 1 diabetes and inflammatory bowel disease. Enthera's pipeline targets key pathways involved in cell apoptosis in the gut, pancreas, and other organs to combat these intractable conditions effectively.

Jacobio Pharmaceuticals, established in 2015 in Beijing, China, is a clinical-stage biotech company specializing in the discovery and development of innovative therapies, particularly in oncology. The company aims to address unmet medical needs both in China and globally, focusing on serious diseases such as cancer, autoimmune disorders, and infectious diseases. Founded by experienced executives with a strong track record in the pharmaceutical industry, Jacobio has rapidly built a skilled research and development team of over 100 employees. This team possesses comprehensive capabilities in target discovery, medicinal chemistry, pharmacology, and clinical registration. Jacobio has developed a robust pipeline of 8 to 10 drug candidates, with JAB-3068 being the most advanced program. This candidate targets novel pathways for both immunotherapy and targeted therapies and has entered Phase I clinical trials in the United States, with additional trials planned in China.

Accent Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapies for oncology, utilizing the emerging field of epitranscriptomics. Founded in 2017 and headquartered in Lexington, Massachusetts, the company explores the post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting cancer-associated RNA-modifying proteins, Accent Therapeutics aims to innovate and deliver transformative therapies that can significantly improve patient outcomes in cancer treatment.

Nitrase Therapeutics is a biopharmaceutical company focused on developing innovative therapies targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create treatments that may slow or halt the progression of this condition. The company leverages its proprietary platform, which is based on the biochemical modification of proteins through nitration, to identify nitro-substrates and their relevance in various diseases. This approach not only addresses Parkinson's but also positions Nitrase to expand its research into other therapeutic indications, with the goal of offering novel medicines that target this specific enzyme pathway.

Quench Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies for inflammatory diseases by targeting gasdermin proteins. The company specializes in gasdermin biology and innate immunity to create innovative medicines. Its lead compounds specifically target and inhibit Gasdermin D, a key protein involved in pyroptosis and NETosis pathways, which play significant roles in the release of inflammatory cytokines, alarmins, DNA, and neutrophil extracellular traps (NETs). Established in 2018 and previously known as Project Pyro, Quench Bio aims to provide effective treatments that alleviate the symptoms of severe inflammatory conditions.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Mavupharma Inc., founded in 2016 and headquartered in the United States, focuses on the development of non-nucleotide, conditional modulators of the STING pathway for the treatment of cancer and infectious diseases. As a subsidiary of AbbVie Inc. since July 2019, Mavupharma leverages small molecules to indirectly and conditionally modulate the STING pathway, harnessing the innate immune system. This innovative approach aims to provide effective oral bioavailable treatments, enhancing therapeutic options for cancer patients and contributing to advancements in medical care.

Allergan plc is a global pharmaceutical company that develops, manufactures, and commercializes a diverse range of branded pharmaceuticals, medical devices, biologics, and regenerative medicine products. The company operates through three primary segments: US Specialized Therapeutics, US General Medicine, and International. Allergan's extensive portfolio includes products across various therapeutic areas, such as medical aesthetics, dermatology, eye care, neuroscience, urology, gastrointestinal health, women's health, and anti-infective treatments. It is particularly known for its flagship product, Botox, along with breast implants and tissue expanders. The company actively collaborates with other organizations to advance its research and development efforts, including partnerships for treating Alzheimer’s disease and other conditions. Allergan was founded in 1950 and has its headquarters in Dublin, Ireland. In 2015, it rebranded from Actavis plc and is currently a subsidiary of AbbVie Inc.

St. Jude Children's Research Hospital, founded in 1962 and located in Memphis, Tennessee, is a non-profit organization dedicated to understanding, treating, and ultimately defeating childhood cancer and other life-threatening diseases. The hospital prioritizes research and treatment aimed at curing and preventing pediatric catastrophic diseases. It manages an endowment fund that supports its strategic initiatives, with assets overseen by a board of governors. St. Jude is committed to ensuring that no patient is ever turned away due to a family's inability to pay, thus emphasizing its mission to advance the health and well-being of children.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

Ribometrix, Inc. is a biotechnology company founded in 2014 and headquartered in Durham, North Carolina. The company specializes in discovering and developing small molecule drugs that target functional three-dimensional RNA structures, aiming to address various human diseases. Ribometrix employs advanced techniques in RNA structural analysis, utilizing proprietary methods and state-of-the-art tools, including artificial intelligence and machine learning, to identify novel small molecules that can inhibit the production of disease-associated proteins. By focusing on RNA biology, Ribometrix seeks to lead a new paradigm in small molecule therapeutics, enhancing the understanding and modulation of RNA's role in disease mechanisms.

Paragen Bio is a biotechnology company focused on developing innovative treatments for autoimmune diseases. Its technology aims to address conditions where the immune system mistakenly attacks healthy tissues and organs. By providing targeted therapies for ailments such as inflammatory bowel disease and asthma, Paragen Bio seeks to enable healthcare providers to improve patient outcomes and enhance the quality of life for those affected by these chronic conditions.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Quentis Therapeutics, Inc. is a biotechnology company founded in 2016 and based in New York, specializing in the development of cancer immunotherapies. The company's innovative therapeutics focus on modulating endoplasmic reticulum (ER) stress response pathways within the tumor microenvironment. By targeting these pathways, Quentis Therapeutics aims to enhance the immune system's ability to combat cancer, thereby providing patients with access to novel treatment options. The company's approach seeks to translate cutting-edge biological insights into effective therapeutic strategies that can improve anti-tumor immunity.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Ribometrix, Inc. is a biotechnology company founded in 2014 and headquartered in Durham, North Carolina. The company specializes in discovering and developing small molecule drugs that target functional three-dimensional RNA structures, aiming to address various human diseases. Ribometrix employs advanced techniques in RNA structural analysis, utilizing proprietary methods and state-of-the-art tools, including artificial intelligence and machine learning, to identify novel small molecules that can inhibit the production of disease-associated proteins. By focusing on RNA biology, Ribometrix seeks to lead a new paradigm in small molecule therapeutics, enhancing the understanding and modulation of RNA's role in disease mechanisms.

Palleon Pharmaceuticals Inc. is a biotechnology company dedicated to developing innovative therapeutics that target glycan-mediated immune regulation for the treatment of cancer and inflammatory diseases. Founded in 2015 and based in Waltham, Massachusetts, the company specializes in glycoimmune checkpoint inhibitors, leveraging advanced insights from glycoscience and human immunology. Palleon's biotechnology platform aims to provide a novel approach to cancer treatment by targeting various immune cell types, thus offering physicians an expanded array of combination therapies to enhance treatment efficacy and address resistance to existing immuno-oncology agents. In addition to cancer, the company also focuses on therapeutics for inflammatory diseases, including autoimmunity and fibrosis.

Exicure, Inc. is a clinical-stage biotechnology company based in Chicago, Illinois, focused on developing therapeutics utilizing its proprietary spherical nucleic acid (SNA) technology. The company aims to address a range of conditions, including neurological disorders, immuno-oncology, inflammatory diseases, and genetic disorders. Its lead drug candidate, AST-008, is currently undergoing Phase 1b/2 clinical trials for advanced solid tumors. Additionally, Exicure is advancing XCUR-FXN, an SNA-based therapeutic for Friedreich’s ataxia in preclinical trials, and XCUR17, which targets the mRNA encoding interleukin 17 receptor alpha. The company has established collaborations with Allergan Pharmaceuticals to develop SNA-based treatments for hair loss and with DERMELIX, LLC for research and commercialization efforts related to netherton syndrome. Founded in 2011, Exicure is developing a new class of immunomodulatory and gene silencing drugs that enhance the delivery and efficacy of nucleic acid therapeutics.

Disarm Therapeutics, Inc. is a biotechnology company founded in 2016 and headquartered in Cambridge, Massachusetts. The company focuses on developing disease-modifying therapeutics aimed at treating neurological diseases characterized by axonal degeneration. Its innovative drugs are designed to prevent the loss of axons, offering potential treatments for conditions such as multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. Disarm Therapeutics aims to provide effective therapies for patients suffering from acute diseases affecting the central, ocular, and peripheral nervous systems. As of late 2020, Disarm Therapeutics operates as a subsidiary of Eli Lilly and Company.

Rodeo Therapeutics Corp. is a Seattle-based drug development company that focuses on creating novel small molecule therapies aimed at tissue repair and regeneration. Founded in 2017, the company targets specific biological pathways and enzyme mechanisms critical for healing. Its primary objectives include developing treatments for inflammatory bowel disease and enhancing blood cell reconstitution after bone marrow transplants. Rodeo's innovative approach involves increasing tissue levels of prostaglandin PGE2 by inhibiting the enzyme 15-PGDH, which has shown promise in protecting against colitis and promoting liver regeneration in various animal models. This research positions Rodeo Therapeutics to contribute significantly to the medical management of these conditions.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Aquinnah Pharmaceuticals, Inc., founded in 2014 and based in Cambridge, Massachusetts, is a pharmaceutical company dedicated to developing therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company focuses on innovative research aimed at modulating neurodegenerative stress granules, which are thought to play a significant role in the pathology of ALS. Through its specialized approach, Aquinnah Pharmaceuticals aims to address critical unmet medical needs in the field of neurodegeneration.

ApoGen Biotechnologies, Inc. is a biotechnology company based in Seattle, Washington, established in 2014. The company specializes in developing innovative therapeutics aimed at addressing the challenges of drug resistance in cancer treatment. Recognizing that the mutation of cellular DNA is central to cancer progression, ApoGen focuses on therapies that target key drivers of genomic mutations and tumor evolution. By doing so, the company aims to slow or halt the ongoing mutations within cancer genomes, which are significant contributors to treatment failure, cancer recurrence, and metastasis. Through its advanced therapeutic approaches, ApoGen Biotechnologies seeks to improve outcomes for patients facing the complexities of cancer evolution and drug resistance.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Morphic Therapeutic is a biotechnology company focused on developing oral integrin therapies to address serious chronic diseases such as autoimmune disorders, cardiovascular issues, metabolic diseases, fibrosis, and cancer. The company leverages its expertise in integrins to create a pipeline of small-molecule inhibitors targeting various integrin pathways. This innovative approach aims to provide effective treatments for patients suffering from immunological, fibrotic, neoplastic, and vascular conditions, contributing to advancements in biopharmaceuticals.

Stemcentrx is a biotechnology company focused on developing innovative therapies aimed at curing cancer and improving patient survival rates. Founded in 2008 by Brian Slingerland and Scott J. Dylla, the company is headquartered in South San Francisco, California. Stemcentrx specializes in creating disease-specific treatments that target cancer stem cells, the cells responsible for initiating and sustaining tumor growth. This approach allows healthcare providers to more effectively address the root causes of cancer, enhancing the potential for successful outcomes for patients. In 2016, Stemcentrx became a subsidiary of AbbVie, further expanding its resources and capabilities in the fight against cancer.

Lodo Therapeutics Corporation is a drug discovery and development company dedicated to creating novel therapeutics derived from natural sources. It focuses on addressing significant health challenges, particularly resistant infectious diseases and cancers, by collaborating with global pharmaceutical companies and leading non-governmental organizations. Founded to realize the scientific vision of Dr. Sean Brady from Rockefeller University, Lodo Therapeutics utilizes a genome-based, culture-independent platform to discover and characterize small molecules sourced from environmental microbial DNA. This innovative approach leverages advancements in DNA sequencing and bioinformatics to explore the untapped potential of microbial evolution, aiming to identify therapeutically valuable pharmaceutical products. Headquartered in New York City at the Alexandria Center for Life Science, Lodo Therapeutics is committed to harnessing the power of nature in the fight against undruggable targets and high unmet medical needs.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

Petra Pharma Corporation is a clinical-stage pharmaceutical company based in New York, focused on discovering and developing innovative therapies that modulate phosphoinositide (PI) signaling pathways for the treatment of cancer and metabolic diseases. Founded in 2015, the company targets novel enzyme pathways that play crucial roles in various cellular processes, such as cell division, growth, trafficking, and signaling. By developing small molecules aimed at these processes, Petra Pharma seeks to create impactful therapeutic options that enhance patient care and improve health outcomes.

Pharmacyclics LLC is a biopharmaceutical company headquartered in Sunnyvale, California, that specializes in developing and commercializing innovative therapies for cancer and immune-mediated diseases. Founded in 1991, the company is known for its flagship product, IMBRUVICA, which is a first-in-class oral therapy approved for various types of blood cancers, including chronic lymphocytic leukemia and mantle cell lymphoma. In addition to IMBRUVICA, Pharmacyclics is engaged in the development of several other therapeutic candidates, including a BTK inhibitor currently in multiple phases of clinical trials targeting various malignancies and autoimmune conditions. The company also has ongoing projects involving an HDAC inhibitor for relapsed lymphomas and solid tumors, as well as a Factor VIIa inhibitor for cancer treatment. Pharmacyclics operates as a subsidiary of AbbVie Inc. and collaborates with Janssen Biotech, Inc. to enhance its oncology portfolio.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Virobay Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California, specializing in the development and commercialization of innovative drugs targeting neuropathic pain, autoimmune diseases, liver fibrosis, cancer, and Alzheimer's disease. The company employs a cysteine cathepsin platform to address significant unmet medical needs, creating therapies that regulate essential cellular processes. Its key products include VBY-129, a cathepsin S inhibitor for neuropathic pain and Crohn’s disease; VBY-376, an orally-delivered cathepsin B inhibitor for liver fibrosis in nonalcoholic steatohepatitis; and VBY-825, which targets autoimmune attacks on bile ducts and promotes fibrosis reversal. Additionally, Virobay has licensed VBY-891 to LEO Pharma A/S for specific dermatological applications, such as psoriasis. Founded in 2006, Virobay is committed to advancing treatments that improve patient outcomes in various challenging health conditions.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

ImmuVen is a biotechnology company specializing in the discovery and development of novel biotherapeutics for treating infectious diseases, cancer, and autoimmune disorders. Its proprietary technology enables rapid selection and optimization of soluble T-cell receptor (TCR) receptors, facilitating targeted therapies for various health conditions.

Exicure, Inc. is a clinical-stage biotechnology company based in Chicago, Illinois, focused on developing therapeutics utilizing its proprietary spherical nucleic acid (SNA) technology. The company aims to address a range of conditions, including neurological disorders, immuno-oncology, inflammatory diseases, and genetic disorders. Its lead drug candidate, AST-008, is currently undergoing Phase 1b/2 clinical trials for advanced solid tumors. Additionally, Exicure is advancing XCUR-FXN, an SNA-based therapeutic for Friedreich’s ataxia in preclinical trials, and XCUR17, which targets the mRNA encoding interleukin 17 receptor alpha. The company has established collaborations with Allergan Pharmaceuticals to develop SNA-based treatments for hair loss and with DERMELIX, LLC for research and commercialization efforts related to netherton syndrome. Founded in 2011, Exicure is developing a new class of immunomodulatory and gene silencing drugs that enhance the delivery and efficacy of nucleic acid therapeutics.